Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.

ABSTRACT:

Importance

Biologics are important in treating patients with hidradenitis suppurativa (HS). However, to our knowledge, data on their real-life performance and treatment patterns in HS are limited.

Objective

To examine the drug survival of biologic therapies for HS in a real-world setting.

Design, setting, and participants

This cohort study included all patients with HS between January 1, 2005, and December 31, 2018, who were treated with biologics at the 5 academic hospital clinics where all biologic treatment for HS is conducted in Denmark. Biologics included adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab, and ustekinumab. Data were analyzed between June 1, 2021, and June 20, 2021.

Main outcomes and measures

Drug survi

SUBMITTER: Ring HC 

PROVIDER: S-EPMC8637394 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature